Skip to main content
Ardelyx to file NDA of IBS drug next year
10/12/2017

Ardelyx's tenapanor, or RDX5791, met the primary and secondary endpoints in a late-stage study measuring its ability to treat irritable bowel syndrome with constipation versus a placebo after failing to meet one of its secondary endpoints in an earlier Phase III trial in the spring. The company plans to file a new-drug application with the FDA in the second half of next year.

Full Story: